These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 23337211)

  • 1. Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H2 receptor antagonists.
    Barkun AN; Adam V; Martel M; Bardou M
    Value Health; 2013; 16(1):14-22. PubMed ID: 23337211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Histamine
    Hammond DA; Kathe N; Shah A; Martin BC
    Pharmacotherapy; 2017 Jan; 37(1):43-53. PubMed ID: 27809338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.
    Leontiadis GI; Sreedharan A; Dorward S; Barton P; Delaney B; Howden CW; Orhewere M; Gisbert J; Sharma VK; Rostom A; Moayyedi P; Forman D
    Health Technol Assess; 2007 Dec; 11(51):iii-iv, 1-164. PubMed ID: 18021578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
    Harris RA; Kuppermann M; Richter JE
    Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastrointestinal bleeding.
    Al-Sabah S; Barkun AN; Herba K; Adam V; Fallone C; Mayrand S; Pomier-Layrargues G; Kennedy W; Bardou M
    Clin Gastroenterol Hepatol; 2008 Apr; 6(4):418-25. PubMed ID: 18304891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of histamine receptor-2 antagonist versus proton pump inhibitor for stress ulcer prophylaxis in critically ill patients*.
    MacLaren R; Campbell J
    Crit Care Med; 2014 Apr; 42(4):809-15. PubMed ID: 24365863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proton pump inhibitors vs. histamine 2 receptor antagonists for stress-related mucosal bleeding prophylaxis in critically ill patients: a meta-analysis.
    Barkun AN; Bardou M; Pham CQ; Martel M
    Am J Gastroenterol; 2012 Apr; 107(4):507-20; quiz 521. PubMed ID: 22290403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prophylaxis for stress ulcer bleeding in the intensive care unit].
    Avendaño-Reyes JM; Jaramillo-Ramírez H
    Rev Gastroenterol Mex; 2014; 79(1):50-5. PubMed ID: 24629722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Proton pump inhibitor H2 receptor antagonist].
    Shiotani A; Kamada T; Kusunoki H; Manabe N; Haruma K
    Nihon Rinsho; 2011 Jun; 69(6):1032-8. PubMed ID: 21688623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.
    Gerson LB; Robbins AS; Garber A; Hornberger J; Triadafilopoulos G
    Am J Gastroenterol; 2000 Feb; 95(2):395-407. PubMed ID: 10685741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials.
    Scally B; Emberson JR; Spata E; Reith C; Davies K; Halls H; Holland L; Wilson K; Bhala N; Hawkey C; Hochberg M; Hunt R; Laine L; Lanas A; Patrono C; Baigent C
    Lancet Gastroenterol Hepatol; 2018 Apr; 3(4):231-241. PubMed ID: 29475806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components.
    de Groot NL; Spiegel BM; van Haalen HG; de Wit NJ; Siersema PD; van Oijen MG
    Value Health; 2013; 16(5):769-77. PubMed ID: 23947970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Bleeding and pneumonia in intensive care unit patients given proton pump inhibitor or histamine-2 receptor antagonist for prevention of stress ulcer: a Meta analysis].
    Zhou JF; Wan XY; Huang W; Han LL
    Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2010 Apr; 22(4):221-5. PubMed ID: 20398466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonsteroidal anti-inflammatory drugs: add an anti-ulcer drug for patients at high risk only. Always limit the dose and duration of treatment with NSAIDs.
    Prescrire Int; 2011 Sep; 20(119):216-9. PubMed ID: 21954519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumonia prevention in intubated patients given sucralfate versus proton-pump inhibitors and/or histamine II receptor blockers.
    Grindlinger GA; Cairo SB; Duperre CB
    J Surg Res; 2016 Dec; 206(2):398-404. PubMed ID: 27884335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness and budget impact of intravenous versus oral proton pump inhibitors in peptic ulcer hemorrhage.
    Spiegel BM; Dulai GS; Lim BS; Mann N; Kanwal F; Gralnek IM
    Clin Gastroenterol Hepatol; 2006 Aug; 4(8):988-997. PubMed ID: 16844422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pragmatic assessment of proton pump inhibitors vs. histamine type 2 receptor antagonists on clinically important gastrointestinal bleeding and mortality when used for stress ulcer prophylaxis in the ICU.
    Boyd C; Hassig T; MacLaren R
    Pharmacotherapy; 2021 Oct; 41(10):820-827. PubMed ID: 34478588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial.
    Kantorova I; Svoboda P; Scheer P; Doubek J; Rehorkova D; Bosakova H; Ochmann J
    Hepatogastroenterology; 2004; 51(57):757-61. PubMed ID: 15143910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit.
    MacLaren R; Reynolds PM; Allen RR
    JAMA Intern Med; 2014 Apr; 174(4):564-74. PubMed ID: 24535015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in utilisation of gastroprotective drugs between 2001 and 2005 in Australia and Nova Scotia, Canada.
    Tett SE; Sketris I; Cooke C; van Zanten SV; Barozzi N
    Pharmacoepidemiol Drug Saf; 2013 Jul; 22(7):735-43. PubMed ID: 23559528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.